Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schmidinger

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Gynecologic Oncology|April 9, 2018
Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancerJoyce Liu, Shibani Nicum, Peter Reichardt, et al.
Oncology|June 26, 2013
Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapyAgnes Maj-Hes, Jacques Medioni, Florian Scotte, et al.
Wiener Medizinische Wochenschrift (1946)|July 3, 2003
Aerobic exercise as additive palliative treatment for a patient with advanced hepatocellular cancerRichard Crevenna, Manuela Schmidinger, Mohammad Keilani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis StudyJonas Ahlbrecht, Boris Dickmann, Cihan Ay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinomaManuela Schmidinger, Christoph C Zielinski, Ursula M Vogl, et al.
Cancer|September 17, 2010
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?Manuela Schmidinger, Ursula M Vogl, Marija Bojic, et al.
Anti-Cancer Drugs|March 27, 2002
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factorCatharina Wenzel, Gottfried J Locker, Manuela Schmidinger, et al.
Anti-Cancer Drugs|April 18, 2008
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001Michael Hejna, Markus Raderer, Johannes Zacherl, et al.
American Journal of Clinical Oncology|June 10, 2011
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinomaManuela Schmidinger, Cezary Szczylik, Cora N Sternberg, et al.
Future Oncology (London, England)|February 8, 2023
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapyRobert J Motzer, Manuela Schmidinger, Masatoshi Eto, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology|April 9, 2018
Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancerJoyce Liu, Shibani Nicum, Peter Reichardt, et al.
Oncology|June 26, 2013
Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapyAgnes Maj-Hes, Jacques Medioni, Florian Scotte, et al.
Wiener Medizinische Wochenschrift (1946)|July 3, 2003
Aerobic exercise as additive palliative treatment for a patient with advanced hepatocellular cancerRichard Crevenna, Manuela Schmidinger, Mohammad Keilani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis StudyJonas Ahlbrecht, Boris Dickmann, Cihan Ay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinomaManuela Schmidinger, Christoph C Zielinski, Ursula M Vogl, et al.
Cancer|September 17, 2010
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?Manuela Schmidinger, Ursula M Vogl, Marija Bojic, et al.
Anti-Cancer Drugs|March 27, 2002
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factorCatharina Wenzel, Gottfried J Locker, Manuela Schmidinger, et al.
Anti-Cancer Drugs|April 18, 2008
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001Michael Hejna, Markus Raderer, Johannes Zacherl, et al.
American Journal of Clinical Oncology|June 10, 2011
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinomaManuela Schmidinger, Cezary Szczylik, Cora N Sternberg, et al.
Future Oncology (London, England)|February 8, 2023
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapyRobert J Motzer, Manuela Schmidinger, Masatoshi Eto, et al.
Pageof 12